Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Low proteinuria does not indicate better kidney outcomes or treatment response in patients with lupus nephritis; ...

The addition of obinutuzumab to standard care increased the complete renal response rate by 13.4 percentage points in patients with active proliferative lupus nephritis. At week 76, a significantly ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Brad Rovin, MD: ...

Please provide your email address to receive an email when new articles are posted on . Children treated with belimumab were more likely to achieve primary efficacy renal response vs. standard ...

The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

FDA placed Kezar’s lupus nephritis drug on clinical hold after four fatal adverse events. Kezar says the autoimmune hepatitis trial remains unaffected. Feel unsure about the market’s next move? Copy ...